The Maryland bionanotechnology company is engaged in the development of a portfolio of products for the rapid reagent-free detection of microbes, viruses and microbial components based on its advanced, proprietary NanoBindiTM technology.

Avanti NanoSciences has two main areas of immediate application for which product ranges are being commercialized. Along with biopharmaceutical endotoxin removal and detection, the company is also developing food safety aspects of the technology.

In addition, the Maryland Company says its patent pending technology offers future opportunities in certain clinical therapeutic processes, biomarker monitoring, bio defense and food preservation.

Endotoxin is a potentially fatal pyrogen that may be present in injectable drugs and vaccines, medical devices and the water for injection systems found in the pharmaceutical industry. Many biopharmaceuticals which are produced by genetically engineered bacteria contain high levels of endotoxins in their raw form. For safety reasons all drugs must be cleaned of endotoxins in a specific purification process. Meanwhile, in cell based assays endotoxin contamination can greatly influence results.

In the area of biopharmaceuticals, the technology is applied in the detection and removal of endotoxins. Endotoxins are important in medicine and pharmacology as they are the major cause of sepsis in humans. The removal of these contaminants from the processes involved in developing and producing biopharmaceutical drugs is essential for the major pharmaceutical companies. The current product development portfolio includes EndoSneseTM for endotoxin detection, EndoStripTM for endotoxin removal and EndomonTM for real-time monitoring of endotoxins in pharmaceutical grade water purification.

Meanwhile, the food safety testing applications of the technology enable fast and reliable test procedures e.g. the testing of meat, seafood, milk or cheese for pathogenic organisms such as E. coli, Salmonella and Listeria which are major causes of food poisoning. Avanti NanoSciences intends to raise the capital to complete the existing product portfolios (including corresponding approvals) and to advance commercialization activities through further enhancement of sales and marketing functions.

About Avanti NanoSciences Avanti NanoSciences is the leader in the rapidly growing field of rapid detection and biomarker monitoring. Avanti's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, food safety, bionanotechnology, hospital acquired infections, bio defense and broad healthcare markets. The Company headquarters are in Baltimore, Maryland. Further information is available at http://www.anano.at-gc.com/

Contact Information: Jenny Smith Media Relations Avanti Therapeutics www.anano.at-c.com